Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know

Yun Hwan Kim, Do Young Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chemoembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an an-tiangiogenic therapy. Radioembolization with yttrium-90 (90Y) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that 90Y radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after 90Y therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of 90Y radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalOncology (Switzerland)
Volume84
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Yttrium
Hepatocellular Carcinoma
Blood Vessels
Therapeutics
Sample Size
Anatomy
Catheters
Prospective Studies
Neoplasm Metastasis
Lung
Liver
Population
sorafenib

Keywords

  • Hepatocellular carcinoma
  • Transarterial chemoembolization
  • Yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yttrium-90 radioembolization for hepatocellular carcinoma : What we know and what we need to know. / Kim, Yun Hwan; Kim, Do Young.

In: Oncology (Switzerland), Vol. 84, 01.01.2013, p. 34-39.

Research output: Contribution to journalArticle

@article{81612ff9479e4f969b0887204108ef66,
title = "Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know",
abstract = "In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chemoembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an an-tiangiogenic therapy. Radioembolization with yttrium-90 (90Y) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that 90Y radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after 90Y therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of 90Y radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated.",
keywords = "Hepatocellular carcinoma, Transarterial chemoembolization, Yttrium-90",
author = "Kim, {Yun Hwan} and Kim, {Do Young}",
year = "2013",
month = "1",
day = "1",
doi = "10.1159/000345887",
language = "English",
volume = "84",
pages = "34--39",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",

}

TY - JOUR

T1 - Yttrium-90 radioembolization for hepatocellular carcinoma

T2 - What we know and what we need to know

AU - Kim, Yun Hwan

AU - Kim, Do Young

PY - 2013/1/1

Y1 - 2013/1/1

N2 - In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chemoembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an an-tiangiogenic therapy. Radioembolization with yttrium-90 (90Y) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that 90Y radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after 90Y therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of 90Y radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated.

AB - In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chemoembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an an-tiangiogenic therapy. Radioembolization with yttrium-90 (90Y) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that 90Y radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after 90Y therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of 90Y radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated.

KW - Hepatocellular carcinoma

KW - Transarterial chemoembolization

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=84874376178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874376178&partnerID=8YFLogxK

U2 - 10.1159/000345887

DO - 10.1159/000345887

M3 - Article

C2 - 23428856

AN - SCOPUS:84874376178

VL - 84

SP - 34

EP - 39

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -